

Roman Camarda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8192/publications.pdf>

Version: 2024-02-01

10
papers

1,307
citations

933447

10
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

3583
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive analysis of normal adjacent to tumor transcriptomes. Nature Communications, 2017, 8, 1077.	12.8	394
2	Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nature Medicine, 2016, 22, 427-432.	30.7	381
3	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine, 2016, 22, 1321-1329.	30.7	138
4	GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. Cell Chemical Biology, 2016, 23, 567-578.	5.2	122
5	Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology, 2018, 14, 768-777.	8.0	64
6	MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. EMBO Reports, 2017, 18, 569-585.	4.5	55
7	In vivo Reprogramming of Cancer Metabolism by MYC. Frontiers in Cell and Developmental Biology, 2017, 5, 35.	3.7	48
8	MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Reports, 2020, 30, 3368-3382.e7.	6.4	44
9	Oncogene-regulated release of extracellular vesicles. Developmental Cell, 2021, 56, 1989-2006.e6.	7.0	37
10	Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. Human Molecular Genetics, 2015, 24, 7421-7431.	2.9	24